The latest report by IMARC Group, titled “Neuromodulation Market Report by Technology (Internal Neuromodulation, External Neuromodulation), Biomaterial (Metallic Biomaterials, Polymeric Biomaterials, Ceramic Biomaterials), Application (Parkinson's Disease, Epilepsy, Depression, Dystonia, Pain Management, and Others), and Region 2024-2032”, offers a comprehensive analysis of the industry, which comprises insights on the market. The global neuromodulation market size reached US$ 7.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032.
Factors Affecting the Growth of the Neuromodulation Industry:
- Rising Prevalence of Neurological Disorders
The neuromodulation market is significantly driven by the increasing prevalence of neurological disorders such as Parkinson’s disease, epilepsy, chronic pain, and depression. As the global population ages, the incidence of these conditions is expected to rise, creating a higher demand for effective treatment options. Neuromodulation therapies, which involve direct modulation of nerve activity, offer promising results for managing symptoms and improving the quality of life for patients with these disorders. The growing awareness of the benefits of neuromodulation, coupled with the rising number of patients seeking alternative treatments, is propelling the market forward.
- Technological Advancements in Neuromodulation Devices
Technological advancements in neuromodulation devices are a major driver of market growth. Innovations such as rechargeable implants, closed-loop systems, and minimally invasive procedures have significantly enhanced the efficacy, safety, and patient compliance of neuromodulation therapies. These advancements make devices more user-friendly and accessible, broadening their application to a wider range of neurological conditions. Continuous research and development efforts are also leading to the discovery of new neuromodulation techniques and devices, further expanding the market. The improved precision and customization of treatment protocols made possible by these technologies are driving the adoption of neuromodulation therapies in clinical practice.
- Growing Demand for Non-Invasive Treatment Options
The increasing demand for non-invasive and minimally invasive treatment options is another key driver for the neuromodulation market. Patients and healthcare providers are increasingly favoring treatments that offer effective symptom management with fewer risks and shorter recovery times compared to traditional surgical methods. Non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS), have gained popularity for their ability to treat conditions such as depression and chronic pain without the need for invasive procedures. The preference for these safer and more convenient treatment options is contributing to the rapid growth of the neuromodulation market.
For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/neuromodulation-market/requestsample
Competitive Landscape:
The competitive landscape of the market has been studied in the report with detailed profiles of the key players operating in the market.
- Abbott Laboratories
- Bioventus Inc.
- Boston Scientific Corporation
- Helius Medical Technologies
- Integer Holdings Corporation
- LivaNova PLC
- Medtronic plc
- MicroTransponder Inc.
- Neuronetics
- NeuroPace Inc.
- NeuroSigma Inc.
- Nevro Corp.
Neuromodulation Market Report Segmentation:
By Technology:
- Internal Neuromodulation
- Spinal Cord Stimulation (SCS)
- Deep Brain Stimulation (DBS)
- Vagus Nerve Stimulation (VNS)
- Sacral Nerve Stimulation (SNS)
- Gastric Electrical Stimulation (GES)
- External Neuromodulation
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Transcranial Magnetic Stimulation (TMS)
- Others
Internal neuromodulation represents the leading segment due to its direct and targeted stimulation of neural structures, offering effective treatment options for various neurological disorders with minimally invasive procedures.
By Biomaterial:
- Metallic Biomaterials
- Polymeric Biomaterials
- Ceramic Biomaterials
Metallic biomaterials account for the largest market share owing to their biocompatibility, durability, and reliability, making them suitable for long-term implantation in neuromodulation devices.
By Application:
- Parkinson's Disease
- Epilepsy
- Depression
- Dystonia
- Pain Management
- Others
Parkinson’s disease represents the largest segment as it is one of the most prevalent neurological disorders globally, driving demand for neuromodulation therapies to alleviate symptoms such as tremors, rigidity, and bradykinesia.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America's dominance in the neuromodulation market is attributed to factors such as advanced healthcare infrastructure, high prevalence of neurological disorders, supportive regulatory frameworks, and strong investments in research and development.
Global Neuromodulation Market Trends:
The global neuromodulation market is experiencing significant growth driven by the increasing prevalence of neurological disorders, such as chronic pain, Parkinson's disease, and epilepsy, driving demand for neuromodulation therapies as alternative treatment options. Apart from this, ongoing technological advancements in neuromodulation devices, including miniaturization, wireless connectivity, and closed-loop systems, enhance treatment efficacy, patient comfort, and convenience, fueling market growth. Additionally, the expanding applications of neuromodulation beyond traditional indications, such as psychiatric disorders, addiction, and obesity, present new opportunities for market growth. Furthermore, rising healthcare expenditure, improving healthcare infrastructure, and expanding reimbursement coverage for neuromodulation procedures are stimulating market expansion.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5722&flag=C
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
